| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/28/2023 | 64.22% | RBC Capital | $51 → $56 | Maintains | Outperform |
| 11/09/2023 | 34.9% | Wedbush | $47 → $46 | Maintains | Outperform |
| 10/24/2023 | — | Cantor Fitzgerald | Assumes | → Overweight | |
| 09/22/2023 | 49.56% | RBC Capital | → $51 | Reiterates | Outperform → Outperform |
| 08/22/2023 | 70.09% | Cantor Fitzgerald | → $58 | Reiterates | Overweight → Overweight |
| 08/10/2023 | 37.83% | Wedbush | → $47 | Reiterates | Outperform → Outperform |
| 08/10/2023 | 46.63% | Needham | → $50 | Reiterates | Buy → Buy |
| 07/17/2023 | 49.56% | RBC Capital | → $51 | Reiterates | Outperform → Outperform |
| 06/21/2023 | 70.09% | Cantor Fitzgerald | → $58 | Reiterates | Overweight → Overweight |
| 06/15/2023 | 43.7% | Guggenheim | → $49 | Reiterates | Buy → Buy |
| 05/10/2023 | 37.83% | Wedbush | $44 → $47 | Maintains | Outperform |
| 04/25/2023 | 70.09% | Cantor Fitzgerald | → $58 | Initiates Coverage On | → Overweight |
| 04/25/2023 | 61.29% | JP Morgan | $54 → $55 | Maintains | Overweight |
| 04/21/2023 | 46.63% | Needham | → $50 | Reiterates | → Buy |
| 03/22/2023 | 49.56% | RBC Capital | → $51 | Reiterates | → Outperform |
| 03/02/2023 | 46.63% | Needham | $48 → $50 | Maintains | Buy |
| 01/31/2023 | 49.56% | RBC Capital | $49 → $51 | Maintains | Outperform |
| 12/14/2022 | 75.95% | Goldman Sachs | → $60 | Initiates Coverage On | → Buy |
| 12/12/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/28/2022 | 46.63% | Wells Fargo | → $50 | Initiates Coverage On | → Overweight |
| 11/11/2022 | 43.7% | Guggenheim | $53 → $49 | Maintains | Buy |
| 10/19/2022 | 52.49% | Raymond James | → $52 | Initiates Coverage On | → Outperform |
| 10/11/2022 | 43.7% | RBC Capital | $46 → $49 | Maintains | Outperform |
| 08/29/2022 | — | B of A Securities | Initiates Coverage On | → Buy | |
| 08/11/2022 | 34.9% | SVB Leerink | $40 → $46 | Maintains | Outperform |
| 08/10/2022 | 34.9% | RBC Capital | $41 → $46 | Maintains | Outperform |
| 07/21/2022 | 61.29% | JP Morgan | → $55 | Initiates Coverage On | → Overweight |
| 06/27/2022 | 20.23% | Wedbush | $47 → $41 | Maintains | Outperform |
| 05/11/2022 | 20.23% | RBC Capital | $43 → $41 | Maintains | Outperform |
| 11/11/2021 | 17.3% | SVB Leerink | $34 → $40 | Maintains | Outperform |
| 10/28/2021 | 26.1% | RBC Capital | → $43 | Initiates Coverage On | → Outperform |
| 10/04/2021 | 40.76% | Needham | $25 → $48 | Maintains | Buy |
| 03/02/2021 | -26.69% | Needham | $22 → $25 | Maintains | Buy |
| 03/02/2021 | -17.89% | SVB Leerink | $25 → $28 | Maintains | Outperform |
| 10/02/2020 | -35.48% | SVB Leerink | → $22 | Initiates Coverage On | → Outperform |
| 07/21/2020 | -35.48% | Needham | → $22 | Initiates Coverage On | → Buy |
| 06/01/2020 | -32.55% | Jefferies | $16 → $23 | Assumes | → Buy |
| 03/25/2020 | -32.55% | Wedbush | → $23 | Initiates Coverage On | → Outperform |
| 01/08/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 09/20/2019 | -26.69% | Guggenheim | → $25 | Initiates Coverage On | → Buy |
| 03/29/2019 | — | Stifel | Assumes | → Buy |
What is the target price for Xenon Pharmaceuticals (XENE)?
The latest price target for Xenon Pharmaceuticals (NASDAQ: XENE) was reported by RBC Capital on November 28, 2023. The analyst firm set a price target for $56.00 expecting XENE to rise to within 12 months (a possible 64.22% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Xenon Pharmaceuticals (XENE)?
The latest analyst rating for Xenon Pharmaceuticals (NASDAQ: XENE) was provided by RBC Capital, and Xenon Pharmaceuticals maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Xenon Pharmaceuticals (XENE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.
Is the Analyst Rating Xenon Pharmaceuticals (XENE) correct?
While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a maintained with a price target of $51.00 to $56.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $34.10, which is out of the analyst's predicted range.